We used insurance claims to examine the prevalence and prescribing patterns of prescription opioids in a national cohort of individuals experiencing a treated heroin-related overdose between 2010 and 2017.
Telemedicine for treating Substance use disorder (SUD) use is growing steadily among treatment facilities; however, uptake is uneven and relatively low. As such, telemedicine may be an under-utilized tool to expand access to care for patients with SUD.
The existing literature on naloxone access laws in the United States supports beneficial effects for increased naloxone distribution, but provides inconclusive evidence for reduced fatal opioid overdose.
Veterans who have served in the U.S. military since the 9/11 attacks have a high level of need for both substance use treatment and mental health care, yet many do not receive appropriate help for their co-occurring disorders.
This brief highlights important treatment, provider, and system factors that organizations that support the behavioral health needs of veterans with co-occurring substance use disorders and mental health disorders should consider.
Co-occurring substance use and mental health disorders are common among post-9/11 veterans. But treatment programs typically specialize in one issue or the other. Integrated treatments are more effective and have become more available, but it's critical that veterans have access to facilities that are equipped to treat them.
With COVID-19 vaccine development well underway, implementation of a vaccination program warrants attention. Vaccine effectiveness demands a certain percentage uptake. But since health care delivery in the United States is fragmented, a coherent federal intervention may be necessary.
Experts consider how monitoring the development of a COVID-19 vaccine could help to identify which of the approaches speeding development and deployment could be usefully applied more widely in the future.
We review the change over time in state-level policy environments around substance use in pregnancy and contrast the policy response with the principles and guidance from professional societies and federal agencies.
Innovating in response to public health challenges like COVID-19 does not always align well with pharmaceutical industry commercial models or shareholder expectations. More sustainable and scalable ways of incentivizing innovation in response to infectious disease threats are needed.
With scientists striving for a viable coronavirus vaccine, and public health officials considering its potential rollout, do calls for freedom of choice and anti-vaccination sentiments, as seen in recent televised protests, represent a worrying omen?
A study examined the rates of hospitalisation or death related to severe bacteria infections among people who inject heroin in South London, England. The report compared these rates to the general population and calculated the cost of admissions.